View More Recent Stories

Mar 6, 2025 06:09AM Zymeworks (ZYME) PT Raised to $19 at Citi
Mar 5, 2025 04:30PM Zymeworks (ZYME) Misses Q4 EPS by 31c
Feb 26, 2025 06:07AM Zymeworks (ZYME) Achieves $14M Milestone from GSK Collaboration
Dec 16, 2024 06:16AM JPMorgan Upgrades Zymeworks (ZYME) to Overweight
Dec 12, 2024 08:33AM Zymeworks (ZYME) Hosts R&D Day Highlighting Continued Clinical Progress in Oncology Programs and Expansion into Autoimmune and Inflammatory Diseases
Nov 21, 2024 09:22AM Zymeworks (ZYME) PT Raised to $26 at Leerink Partners
Nov 21, 2024 06:01AM Zymeworks (ZYME): FDA Grants U.S. Approval of Ziihera® (zanidatamab-hrii) for the Treatment of Adults with Previously Treated
Nov 7, 2024 06:19AM Leerink Partners Upgrades Zymeworks (ZYME) to Outperform, 'Time to Get Constructive on ZYME?'
Nov 1, 2024 07:25AM Wells Fargo Downgrades Zymeworks (ZYME) to Equal Weight
Oct 31, 2024 04:35PM Zymeworks (ZYME) Misses Q3 EPS by 39c
Oct 28, 2024 07:48AM Zymeworks (ZYME) PT Raised to $28 at Stifel
Oct 22, 2024 06:57AM H.C. Wainwright Reiterates Neutral Rating on Zymeworks (ZYME)
Oct 18, 2024 04:11PM Zymeworks (ZYME) Announces Resignation of Hollings C. Renton
Sep 25, 2024 06:37AM Zymeworks (ZYME) PT Raised to $12 at H.C. Wainwright
Sep 18, 2024 06:41AM H.C. Wainwright Reiterates Neutral Rating on Zymeworks (ZYME)
Sep 10, 2024 07:29AM Stifel Reiterates Buy Rating on Zymeworks (ZYME)
Aug 1, 2024 05:02PM Zymeworks (ZYME) Misses Q2 EPS by 49c
Aug 1, 2024 04:12PM Zymeworks (ZYME) Announces $60M Share Buyback
Jul 25, 2024 04:30PM Zymeworks (ZYME) Appoints Leone Patterson as Chief Business and Financial Officer
Jul 22, 2024 06:01AM Zymeworks (ZYME) Receives FDA Clearance of Investigational New Drug Application for ZW191
Jun 17, 2024 06:00AM Zymeworks (ZYME) Announces FDA Clearance of IND Application for ZW171
Jun 10, 2024 05:01AM Zymeworks (ZYME) Announces China NMPA Acceptance of BLA for Zanidatamab
View More Recent Stories